In EGFR-mutant NSCLC cells, PD-L1 upregulates TGF-β signaling to activate the EMT pathway, thereby contributing to acquired resistance to gefitinib [47]. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.